Celcuity, Inc. $CELC Stock Sold by Simplicity Wealth LLC

Key Points

• Simplicity Wealth LLC cut its Celcuity stake by 95.7% in the third quarter, selling 104,812 shares and retaining 4,671 shares valued at approximately $371,000.
• Other institutional investors increased their positions, led by Assenagon Asset Management’s 685.9% increase to 1.48 million shares. Institutional investors collectively own 63.33% of Celcuity.
• Celcuity shares opened at $69.13, near the lower end of their 52-week range, after the company reported a quarterly EPS loss of $1.44 versus the $1.16 expected. Analysts maintain a “Moderate Buy” consensus with an average price target of $152.57.

Simplicity Wealth LLC decreased its holdings in Celcuity, Inc. (NASDAQ:CELC - Free Report) by 95.7% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,671 shares of the company's stock after selling 104,812 shares during the quarter. Simplicity Wealth LLC's holdings in Celcuity were worth $371,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Sterling Capital Management LLC grew its holdings in Celcuity by 840.7% in the third quarter. Sterling Capital Management LLC now owns 1,270 shares of the company's stock valued at $101,000 after purchasing an additional 1,135 shares during the last quarter. IFP Advisors Inc raised its stake in shares of Celcuity by 42.6% during the 3rd quarter. IFP Advisors Inc now owns 995 shares of the company's stock worth $79,000 after buying an additional 297 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Celcuity by 685.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,478,607 shares of the company's stock worth $117,579,000 after buying an additional 1,290,466 shares during the last quarter. Envestnet Asset Management Inc. boosted its position in shares of Celcuity by 358.3% in the 2nd quarter. Envestnet Asset Management Inc. now owns 15,958 shares of the company's stock worth $1,670,000 after buying an additional 12,476 shares in the last quarter. Finally, Engineers Gate Manager LP purchased a new stake in shares of Celcuity in the 2nd quarter worth about $480,000. Institutional investors and hedge funds own 63.33% of the company's stock.

Celcuity Trading Down 0.2%

Shares of CELC stock opened at $69.13 on Friday. The company has a quick ratio of 8.93, a current ratio of 8.93 and a debt-to-equity ratio of 6.04. The stock has a market cap of $3.38 billion, a price-to-earnings ratio of -16.08 and a beta of 0.10. The firm's 50 day moving average price is $77.67 and its two-hundred day moving average price is $100.37. Celcuity, Inc. has a fifty-two week low of $53.54 and a fifty-two week high of $151.02.

Celcuity (NASDAQ:CELC - Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.28). On average, analysts anticipate that Celcuity, Inc. will post -4.98 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on CELC shares. Citizens Jmp restated a "market outperform" rating and set a $177.00 target price on shares of Celcuity in a report on Monday, August 17th. Weiss Ratings restated a "sell (d-)" rating on shares of Celcuity in a research report on Tuesday, September 1st. HC Wainwright reaffirmed a "buy" rating and issued a $155.00 price target on shares of Celcuity in a report on Friday, August 14th. Guggenheim increased their price target on shares of Celcuity from $165.00 to $175.00 and gave the company a "buy" rating in a research report on Monday, August 17th. Finally, Royal Bank Of Canada lowered shares of Celcuity to a "neutral" rating in a research report on Wednesday. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Celcuity presently has an average rating of "Moderate Buy" and an average price target of $152.57.

Celcuity Profile

Celcuity, Inc is a clinical-stage biotechnology company developing functional diagnostic tests designed to help identify cancer treatments that may be most effective for individual patients. Its technology analyzes living tumor cells taken from patients to measure how signaling pathways respond to different therapies, with the goal of supporting more personalized treatment decisions.

The company's CELsignia platform is designed to assess the activity of cancer-related signaling pathways in patient-derived cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.